AAV Capsid Content Analysis Market (2026 - 2033)

AAV Capsid Content Analysis Market Summary

The global AAV capsid content analysis market size was valued at USD 182.0 million in 2025 and is projected to grow from USD 201.1 million in 2026 to USD 427.1 million by 2033, at a CAGR of 11.4% from 2026 to 2033. The market in North America dominated with a revenue share of 48.0% in 2025. The industry is driven by increasing adoption of gene therapy and viral vector technologies, growing demand for precise AAV characterization, and expanding applications of capsid analysis in gene therapy development, vector quality assessment, and biopharmaceutical manufacturing.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

The industry is witnessing significant growth, driven by the expanding development and manufacturing of AAV-based gene therapies and increasing demand for accurate characterization of viral-vector quality. Growing adoption of analytical techniques for quantifying full, empty, and partially filled capsids is enabling improved assessment of product purity, potency, safety, and manufacturing consistency. In addition, increasing regulatory requirements for comprehensive AAV characterization, along with advances in analytical ultracentrifugation, chromatography, mass photometry, electron microscopy, and charge-detection mass spectrometry, are supporting market growth.

Market Concentration & Characteristics

The degree of innovation in the industry is high, driven by advances in multiplexed analysis, high-throughput characterization, and simultaneous assessment of capsid and transgene content. For instance, in March 2024, NanoMosaic launched AAV bioprocessing and manufacturing QC assays on its Tessie platform, enabling simultaneous characterization of AAV capsids and therapeutic transgenes. The platform quantifies full, empty, and partial capsids from crude extracts in a single workflow, improving analytical efficiency and supporting AAV process development and manufacturing.

"NanoMosaic is excited to offer a unique solution to a challenging and fast-growing gene therapy market. In addition to AAV characterization applications, we remain committed to empowering the scientific community with high-plex and multi-omic solutions for biomarker research and diagnostics.

-Qimin Quan, PhD, co-founder and Chief Scientific Officer, NanoMosaic

To learn more about this report, Download Free Sample Report

The industry is witnessing moderate M&A activity, supported by acquisitions that expand specialized AAV analytical and development capabilities. For instance, in April 2024, Ascend Advanced Therapies completed the acquisition of Beacon Therapeutics’ CMC team and GMP site in Alachua, Florida, adding process and analytical development capabilities for AAV products. The acquisition strengthens Ascend’s analytical services and CDMO capabilities, supporting AAV characterization, quality assessment, and process development activities.

“This acquisition allows us to now support customers from research through to commercialization and adds to one of the most experienced gene therapy teams in the market. Every day we are working together to grow the company with a long-term mindset of quality first to appropriately balance quality and yield for the life of each product."

- Mike Stella, CEO at Ascend

The impact of regulations on the industry is high, as regulatory requirements emphasize the characterization, quality, purity, and consistency of gene therapy products. These requirements increase the need for reliable analytical methods to evaluate AAV capsid content and related product attributes. Consequently, regulatory expectations support the adoption of specialized instruments, consumables, and analytical services for capsid characterization across process development, quality control, and lot release applications.

The industry is witnessing product expansion through the introduction of specialized reference materials for capsid characterization. For instance, in May 2024, Charles River Laboratories launched six AAV reference material serotypes with defined empty and full capsid ratios and high vector genome concentrations. These reference materials support analytical method development, assay calibration, and quality control for AAV capsid content analysis, supporting process development and lot release applications.

The industry is witnessing regional expansion as analytical testing providers expand specialized capabilities for AAV gene therapies. For instance, in May 2024, Solvias announced the development of a 50,000-square-foot analytical testing center in Research Triangle Park, North Carolina, to support characterization and release testing of AAV gene therapies. The facility expanded Solvias’ U.S. analytical services and strengthened regional access to testing capabilities supporting AAV development and quality control.

“Our new center strongly complements our biologics and CGT sites in Europe and expands our world-class testing capabilities in the U.S. Our team is thrilled to bring our newest center of excellence to Research Triangle Park, a leading research and development center and burgeoning hub for the life science industry. We will continue to invest in expanding our capabilities to support our customers with their critical work of developing and maintaining life-changing therapies.”

- Archie Cullen, CEO of Solvias

Analyst Perspective

The industry is supported by the expanding development of AAV-based gene therapies and increasing emphasis on viral vector quality assessment. As manufacturers seek to improve product consistency and process efficiency, demand is expected to rise for analytical solutions that accurately quantify full, empty, and partially filled capsids. The need for reliable characterization across process development, quality control, and lot release is also shaping technology adoption. Market participants are focusing on advancing chromatography, mass photometry, and mass spectrometry platforms, while developing faster, more precise, and workflow-compatible solutions to support AAV characterization and manufacturing requirements.

Product & Service Insights

The instruments segment accounted for the largest revenue share of 45.9% in 2025, supported by increasing demand for accurate and efficient characterization of AAV capsid content. For instance, according to an article published in Analytical Chemistry in October 2024, researchers demonstrated the use of Orbitrap-based charge detection mass spectrometry (CDMS) to characterize AAV vectors by evaluating empty-to-full capsid ratios, encapsidated genome mass, and viral protein stoichiometry. The technique enabled the analysis of multiple critical quality attributes using a single analytical approach, highlighting the role of advanced mass spectrometry instruments.

The services segment is expected to register the fastest CAGR during 2026-2033, driven by the complexity of AAV-based gene therapies and the need for specialized analytical expertise. Service providers offer testing and characterization solutions to assess capsid composition, including the distribution of empty, partial, and full capsids. Outsourcing these analyses enables biopharmaceutical companies to access advanced analytical technologies and technical expertise without substantial investments in specialized equipment, while supporting quality control and consistency throughout AAV development and manufacturing.

Technology Insights

The chromatography (AEX-HPLC, SEC-MALS) segment dominated the market with a share of 25.5% in 2025, supported by the need for reliable methods to characterize AAV capsid content and product quality. AEX-HPLC enables the separation of empty and full capsids, while SEC-MALS supports the assessment of capsid content, aggregation, and genome titer. According to a research article published in Molecular Therapy Methods & Clinical Development in November 2024, researchers developed a size-exclusion chromatography-based multi-attribute monitoring method using UV, fluorescence, multi-angle light scattering, and refractive index detectors to assess AAV genome and capsid titers, purity, aggregation, and full-to-empty capsid ratios within a single assay. The method produced results comparable to established analytical techniques, highlighting the potential of advanced chromatography for comprehensive AAV quality assessment.

The mass photometry segment is expected to register the fastest CAGR during 2026-2033, driven by increasing demand for rapid, sensitive, and low-sample-volume techniques for AAV capsid characterization. Mass photometry enables the quantification of empty, partially filled, and full capsid populations, supporting the assessment of genome packaging and product quality. For instance, according to an article published in Molecular Therapy Nucleic Acids in June 2025, researchers demonstrated that mass photometry could quantify empty, partially filled, and full AAV capsids across samples with varying genome-loading levels, with results comparable to analytical ultracentrifugation. The study highlighted the technique's accuracy, reproducibility, rapid analysis, and low sample consumption for AAV characterization.

Application Insights

The process development & optimization segment accounted for 40.7% of the revenue in 2025, mainly due to the increasing need to improve AAV production efficiency, purification performance, and product quality. The growing emphasis on improving full-capsid recovery, reducing impurities, and ensuring consistent product quality is expected to drive the adoption of analytical techniques throughout process development and scale-up activities.

The quality control & lot release segment is projected to register the fastest CAGR during 2026-2033, driven by stringent quality requirements for gene therapy products and the need to ensure batch-to-batch consistency. AAV capsid content analyses provide critical information for evaluating product quality against predefined specifications before release. The growing focus on analytical reliability, regulatory compliance, and consistent manufacturing outcomes is expected to increase the adoption of capsid characterization techniques in quality control and lot release testing.

Development Stage Insights

The clinical segment accounted for 52.5% of the global revenue, supported by increasing development of AAV-based gene therapies and the need to evaluate vector quality, safety, and therapeutic potency before and during clinical development. According to a research article published in Gene Therapy in February 2024, researchers evaluated the impact of full, intermediate, and empty AAV capsids on vector potency using in vitro and in vivo assays. The research found that intermediate capsids contributed to measured vector genome titers but did not contribute to product potency, highlighting the importance of capsid content characterization in evaluating AAV candidates for clinical development.

The commercial segment is projected to register the fastest CAGR during 2026-2033, driven by increasing need for standardized analytical methods and reliable quality assessment of AAV-based gene therapies. Accurate characterization of empty, partial, and full capsids helps manufacturers establish consistent quality specifications, validate analytical methods, and support batch quality assessment. Continued advancements in reference materials and analytical characterization techniques are expected to strengthen quality control practices and support the transition of AAV therapies toward commercial manufacturing.

End Use Insights

The pharmaceutical & biotechnology companies segment accounted for a 48.9% share in 2025, making it the leading end use segment. Growth is driven by increasing investments in AAV-based gene therapies and the need for effective analytical methods to ensure product quality. The growing focus on optimizing manufacturing processes, improving vector purity, and meeting stringent quality requirements is expected to increase the adoption of advanced capsid characterization techniques across pharmaceutical and biotechnology development programs.

To learn more about this report, Download Free Sample Report

The CDMOs segment is projected to witness the fastest CAGR during 2026-2033, supported by increasing outsourcing of AAV vector development, manufacturing, and analytical testing by pharmaceutical and biotechnology companies. CDMOs utilize AAV capsid content analysis to assess purification efficiency and monitor product quality throughout manufacturing. The growing demand for specialized analytical expertise, scalable production processes, and consistent batch quality is expected to encourage the adoption of advanced capsid characterization techniques among CDMOs supporting gene therapy developers.

Regional Insights

The North America AAV capsid content analysis market dominated, accounting for the largest revenue share of 48.0% in 2025. The regional industry is driven by the expanding development of AAV-based gene therapies and increasing emphasis on accurate assessment of capsid quality attributes. Growing demand to evaluate empty, full, and partially filled capsids, along with capsid purity and genome content, is driving adoption of advanced analytical technologies across AAV development and manufacturing in the region.

To learn more about this report, Download Free Sample Report

U.S. AAV Capsid Content Analysis Market Trends

The AAV capsid content analysis market in the U.S. is expected to grow over the forecast period, supported by increasing emphasis on standardized measurement of critical capsid attributes for AAV-based gene therapies. For instance, in December 2024, the U.S. National Institute of Standards and Technology (NIST) published an interlaboratory study evaluating methods for quantifying full and empty AAV capsids and measuring the full-to-total capsid ratio. The study supports analytical standardization and comparability of AAV measurements, strengthening the adoption of reliable capsid analysis methods for gene therapy development and quality assessment

Europe AAV Capsid Content Analysis Market Trends

The AAV capsid content analysis market in Europe is anticipated to grow significantly over the forecast period, supported by increasing demand for rapid and reliable assessment of genome-containing and genome-lacking AAV particles during gene therapy development and manufacturing. According to an article published in Analytical and Bioanalytical Chemistry in March 2026, researchers from the University of Ulm and Hahn-Schickard in Germany demonstrated the feasibility of infrared attenuated total reflection spectroscopy combined with multivariate data analysis for classifying and quantifying full and empty AAV2 capsids. The approach supports rapid capsid content assessment and potential process monitoring in AAV production.

The UK AAV capsid content analysis industry is expected to grow significantly over the forecast period. In June 2025, Oxford-based Refeyn announced that its mass photometry technology was recognized by the U.S. Pharmacopeia as an orthogonal method for characterizing empty and full AAV capsids in its new AAV reference standards. This development supports greater standardization of capsid content analysis and adoption of advanced analytical technologies for AAV quality assessment.

“We are thrilled that mass photometry has been recognized by the USP for the characterization of empty, full, and—critically—partially filled AAV capsids, and that it is specifically referenced in the new USP general chapter <1067> as a recommended orthogonal method. Along with prior recognition by the British Pharmacopeia, this demonstrates that mass photometry is being accepted as a valuable part of the AAV analytics toolbox. And it has a lot to offer because it is a simple, easy-to-use method for measuring a significant CQA while ensuring consistent and reliable analytics.”

- Gabriella Kiss, Market Development Director at Refeyn.

The AAV capsid content analysis market in Germany is anticipated to grow significantly over the forecast period. The growing emphasis on analytical quality control and process optimization is driving adoption of chromatography, mass spectrometry, and other advanced technologies for capsid content assessment. In addition, the expansion of commercial AAV analytical testing and process-development capabilities is supporting broader use of capsid content analysis solutions.

Asia Pacific AAV Capsid Content Analysis Market Trends

The AAV capsid content analysis market in Asia Pacific is expected to grow at the fastest CAGR of 12.4% during the forecast period, supported by advancement of AAV-based gene therapy development and increasing emphasis on product quality assessment across regional biopharmaceutical markets. Efforts to strengthen regulatory alignment and manufacturing quality standards across countries such as China, Japan, India, and South Korea are increasing the importance of reliable analytical methods.

The China AAV capsid content analysis industry is expected to grow over the forecast period, supported by the expansion of AAV-based gene therapy development and increasing emphasis on quality control of viral vector products. As the country advances its gene therapy pipeline and strengthens regulatory oversight of innovative biologics, demand for reliable measurement of full, empty, and partially filled capsids is expected to increase.

The AAV capsid content analysis market in Japan is witnessing rapid growth supported by increasing demand for specialized analytical testing and GMP-compliant quality assessment of AAV-based gene therapies. For instance, in August 2025, Japan-based U-Medico opened a new GMP-compliant analytical center in Minoh, Osaka, to expand quality testing services for biopharmaceuticals and gene therapy vectors. Its analytical portfolio includes measurement of full-to-empty AAV particle ratios using analytical ultracentrifugation and mass photometry, supporting reliable capsid content assessment and quality control during AAV development and manufacturing.

Latin America AAV Capsid Content Analysis Market Trends

The AAV capsid content analysis industry in Latin America is expected to grow steadily over the forecast period, supported by the gradual expansion of gene therapy research and increasing emphasis on quality assessment of viral vectors. As regional biotechnology and biopharmaceutical capabilities develop, reliable capsid content analysis is expected to become increasingly important for AAV vector development and quality control.

MEA AAV Capsid Content Analysis Market Trends

The AAV capsid content analysis market in the Middle East & Africa is growing steadily. Governments across the region, most notably Saudi Arabia, the UAE, and South Africa, are heavily funding specialized biotechnology and genomic initiatives. As these nations pivot toward precision medicine and localized pharmaceutical manufacturing, they are building advanced bio-analytical labs. This infrastructure development creates a footprint for high-end analytical equipment capable of viral vector characterization.

Key AAV Capsid Content Analysis Company Insights

The AAV capsid content analysis industry is characterized by strong competition among companies offering mass photometry, charge detection mass spectrometry, digital PCR, chromatography, biolayer interferometry, analytical ultracentrifugation, and other capsid characterization technologies. Market participants are enhancing their competitive position through new analytical platforms, assay and service introductions, technology enhancements, partnerships, and broader AAV testing capabilities. Competitive differentiation is influenced by analytical sensitivity, measurement speed, workflow compatibility, technology breadth, geographic reach, customer relationships, and use across AAV development, process optimization, quality assessment, and gene therapy manufacturing.

Key AAV Capsid Content Analysis Companies

Some prominent players in the AAV capsid content analysis market include:

• Beckman Coulter Life Sciences (Danaher Corporation)

• Waters Corporation

• Thermo Fisher Scientific Inc.

• Refeyn Ltd.

• Unchained Labs

• Bio-Rad Laboratories, Inc.

• Sartorius AG

• Agilent Technologies, Inc.

• Charles River Laboratories

• Eurofins

Recent Developments:

• In October 2025, Waters Corporation launched the Xevo Charge Detection Mass Spectrometry (CDMS) system, enabling direct mass-based characterization of viral-vector capsids. The technology distinguishes empty, partial, full, and overfull capsids and supports relative quantification of these capsid types in less than 10 minutes per sample, strengthening applications in capsid content analysis.

Waters continues to make strategic investments in large molecules, recognizing that advanced tools for bioanalytical characterization play a critical role in driving therapeutic breakthroughs. Today, we are proud to introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, enabling the precise analysis of previously unmeasurable molecules. We believe the Xevo CDMS will accelerate the global development of genetic medicines and other advanced modalities by providing a greater understanding of the characteristics of large molecules earlier in development, which is crucial for making life-changing therapies more accessible to patients.

-Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation.

• In October 2024, Bio-Rad Laboratories launched the Vericheck ddPCR Empty-Full Capsid Kit, a high-precision analytical solution for AAV vector characterization. The kit simultaneously quantifies AAV capsid and genome titers to determine the percentage of full capsids and assess empty-to-full capsid ratios, strengthening applications in AAV capsid content analysis and gene therapy vector development.

"AAV vectors are a powerful gene therapy tool, but their production can result in the generation of product-related impurities, such as partial or empty capsids, which impact effectiveness and can elicit unwanted immunotoxicity. Determining the ratio of full, partial, and empty capsids is a recurring challenge throughout AAV gene therapy manufacturing, from early-stage development to quality control and release testing. Our new Vericheck ddPCR Empty-Full Capsid Kit delivers unmatched precision and specificity, along with ease of use and high-throughput capabilities, to provide our customers with a comprehensive solution for AAV vector characterization and to help drive the advancement of safe and effective gene therapies."

-Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group.

• In February 2023, Refeyn Ltd. launched the SamuxMP Auto mass photometer for automated AAV capsid analysis. The system enables determination of AAV sample purity, aggregation, and empty-to-full capsid ratios, supporting rapid and reproducible analysis of AAV capsid content during development and manufacturing.

“We are excited to continue the momentum of our new product introductions with the SamuxMP Auto mass photometer. The system builds on the already successful SamuxMP, adding automated liquid handling to increase the efficiency and reliability of AAV characterization for our customers, all while remaining a benchtop instrument. We are committed to innovating and delivering unique and cost-effective solutions to the challenges faced by our customers and anticipate the SamuxMP Auto having a significant impact in the field, helping speed up crucial steps in AAV development and manufacturing pipelines.”

- Matthias Langhorst, CPO, Refeyn

Global AAV Capsid Content Analysis Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AAV capsid content analysis market report based on product & service, technology, application, development stage, end use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments

  • Services

  • Consumables & Reagents

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Chromatography (AEX-HPLC, SEC-MALS)

  • Analytical Ultracentrifugation (AUC)

  • Mass Photometry

  • PCR & ELISA-based Titer Ratio

  • UV/Vis & Light Scattering Spectroscopy

  • Charge Detection Mass Spectrometry (CDMS)

  • Electron Microscopy (TEM, Cryo-EM)

  • Others (CE, cIEF)

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Process Development & Optimization

  • Quality Control & Lot Release

  • Research & Capsid Engineering

• Development Stage Outlook (Revenue, USD Million, 2021 - 2033)

  • Clinical

  • Preclinical

  • Commercial

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • CDMOs

  • CROs & Testing Laboratories

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The AAV capsid content analysis market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each AAV capsid content analysis segment quantified using the revenue-capture definitions in the table below.